|
|
|
201-500 employees
View all
|
|
biotechnology
|
|
465 Route 17 South,Ramsey,NJ,US
|
|
ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906. For more information, please visit the company's website at www.admabiologics.com.
|
ADMA Biologics, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used ADMA Biologics, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact ADMA Biologics, Inc. customer service number call here 561-989-5800. To contact ADMA Biologics, Inc. customer service number in your country click here to find.
Adam Grossman is the CEO of ADMA Biologics, Inc..
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.